Protective Effects of Antioxidants in Huntington’s Disease

an Extensive Review

Musthafa Mohamed Essa, Marzieh Moghadas, Taher Ba-Omar, M. Walid Qoronfleh, Gilles J. Guillemin, Thamilarasan Manivasagam, Arokiasamy Justin-Thenmozhi, Bipul Ray, Abid Bhat, Saravana Babu Chidambaram, Amanda J. Fernandes, Byoung Joon Song, Mohammed Akbar

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Huntington’s disease (HD) is a hereditary neurodegenerative disease of the central nervous system (CNS). Onset of HD occurs between the ages of 30 and 50 years, although few cases are reported among children and elderly. HD appears to be less common in some populations such as those of Japanese, Chinese, and African descent. Clinical features of HD include motor dysfunction (involuntary movements of the face and body, abnormalities in gait, posture and balance), cognitive impairment (obsessive-compulsive disorder), and psychiatric disorders (dementia). Mutation in either of the two copies of a gene called huntingtin (HTT), which codes genetic information for a protein called “huntingtin (Htt)”, precipitates the disease in an individual. Expansion of cytosine–adenine–guanine (CAG) triplet repeats in the HTT gene results in an abnormal Htt protein. Intracellular neuronal accumulation of the mutated Htt protein (mHtt) causes distinctive erratic movements associated with HD. Further, excessive accumulation of the HTT gene repeats causes abnormal production of reactive oxygen species (ROS) and the ensuing mitochondrial (MT) oxidative stress in neurons. Since there is neither a cure nor a promising strategy to delay onset or progression of HD currently available, therapeutics are mainly focusing only on symptomatic management. Several studies have shown that MT dysfunction-mediated oxidative stress is a key factor for the neurodegeneration observed in HD. Supplementation of antioxidants and nutraceuticals has been widely studied in the management of oxidative damage, an associated complication in HD. Therefore, various antioxidants are used as therapeutics for managing and/or treating HD. The present review aimed at delving into the abnormal cellular changes and energy kinetics of the neurons expressing the mHtt gene and the therapeutic roles of antioxidants in HD.

Original languageEnglish
Pages (from-to)739-774
Number of pages36
JournalNeurotoxicity Research
Volume35
Issue number3
DOIs
Publication statusPublished - 15-04-2019
Externally publishedYes

Fingerprint

Huntington Disease
Antioxidants
Oxidative stress
Genes
Nervous System Heredodegenerative Disorders
Neurons
Oxidative Stress
Proteins
Genetic Code
Trinucleotide Repeats
Neurodegenerative diseases
Obsessive-Compulsive Disorder
Dyskinesias
Dietary Supplements
Posture
Gait
Neurology
Psychiatry
Dementia
Kinetic energy

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Toxicology

Cite this

Essa, M. M., Moghadas, M., Ba-Omar, T., Walid Qoronfleh, M., Guillemin, G. J., Manivasagam, T., ... Akbar, M. (2019). Protective Effects of Antioxidants in Huntington’s Disease: an Extensive Review. Neurotoxicity Research, 35(3), 739-774. https://doi.org/10.1007/s12640-018-9989-9
Essa, Musthafa Mohamed ; Moghadas, Marzieh ; Ba-Omar, Taher ; Walid Qoronfleh, M. ; Guillemin, Gilles J. ; Manivasagam, Thamilarasan ; Justin-Thenmozhi, Arokiasamy ; Ray, Bipul ; Bhat, Abid ; Chidambaram, Saravana Babu ; Fernandes, Amanda J. ; Song, Byoung Joon ; Akbar, Mohammed. / Protective Effects of Antioxidants in Huntington’s Disease : an Extensive Review. In: Neurotoxicity Research. 2019 ; Vol. 35, No. 3. pp. 739-774.
@article{f323130110344d11aaa24ce1398cb0a9,
title = "Protective Effects of Antioxidants in Huntington’s Disease: an Extensive Review",
abstract = "Huntington’s disease (HD) is a hereditary neurodegenerative disease of the central nervous system (CNS). Onset of HD occurs between the ages of 30 and 50 years, although few cases are reported among children and elderly. HD appears to be less common in some populations such as those of Japanese, Chinese, and African descent. Clinical features of HD include motor dysfunction (involuntary movements of the face and body, abnormalities in gait, posture and balance), cognitive impairment (obsessive-compulsive disorder), and psychiatric disorders (dementia). Mutation in either of the two copies of a gene called huntingtin (HTT), which codes genetic information for a protein called “huntingtin (Htt)”, precipitates the disease in an individual. Expansion of cytosine–adenine–guanine (CAG) triplet repeats in the HTT gene results in an abnormal Htt protein. Intracellular neuronal accumulation of the mutated Htt protein (mHtt) causes distinctive erratic movements associated with HD. Further, excessive accumulation of the HTT gene repeats causes abnormal production of reactive oxygen species (ROS) and the ensuing mitochondrial (MT) oxidative stress in neurons. Since there is neither a cure nor a promising strategy to delay onset or progression of HD currently available, therapeutics are mainly focusing only on symptomatic management. Several studies have shown that MT dysfunction-mediated oxidative stress is a key factor for the neurodegeneration observed in HD. Supplementation of antioxidants and nutraceuticals has been widely studied in the management of oxidative damage, an associated complication in HD. Therefore, various antioxidants are used as therapeutics for managing and/or treating HD. The present review aimed at delving into the abnormal cellular changes and energy kinetics of the neurons expressing the mHtt gene and the therapeutic roles of antioxidants in HD.",
author = "Essa, {Musthafa Mohamed} and Marzieh Moghadas and Taher Ba-Omar and {Walid Qoronfleh}, M. and Guillemin, {Gilles J.} and Thamilarasan Manivasagam and Arokiasamy Justin-Thenmozhi and Bipul Ray and Abid Bhat and Chidambaram, {Saravana Babu} and Fernandes, {Amanda J.} and Song, {Byoung Joon} and Mohammed Akbar",
year = "2019",
month = "4",
day = "15",
doi = "10.1007/s12640-018-9989-9",
language = "English",
volume = "35",
pages = "739--774",
journal = "Neurotoxicity Research",
issn = "1029-8428",
publisher = "Springer New York",
number = "3",

}

Essa, MM, Moghadas, M, Ba-Omar, T, Walid Qoronfleh, M, Guillemin, GJ, Manivasagam, T, Justin-Thenmozhi, A, Ray, B, Bhat, A, Chidambaram, SB, Fernandes, AJ, Song, BJ & Akbar, M 2019, 'Protective Effects of Antioxidants in Huntington’s Disease: an Extensive Review', Neurotoxicity Research, vol. 35, no. 3, pp. 739-774. https://doi.org/10.1007/s12640-018-9989-9

Protective Effects of Antioxidants in Huntington’s Disease : an Extensive Review. / Essa, Musthafa Mohamed; Moghadas, Marzieh; Ba-Omar, Taher; Walid Qoronfleh, M.; Guillemin, Gilles J.; Manivasagam, Thamilarasan; Justin-Thenmozhi, Arokiasamy; Ray, Bipul; Bhat, Abid; Chidambaram, Saravana Babu; Fernandes, Amanda J.; Song, Byoung Joon; Akbar, Mohammed.

In: Neurotoxicity Research, Vol. 35, No. 3, 15.04.2019, p. 739-774.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Protective Effects of Antioxidants in Huntington’s Disease

T2 - an Extensive Review

AU - Essa, Musthafa Mohamed

AU - Moghadas, Marzieh

AU - Ba-Omar, Taher

AU - Walid Qoronfleh, M.

AU - Guillemin, Gilles J.

AU - Manivasagam, Thamilarasan

AU - Justin-Thenmozhi, Arokiasamy

AU - Ray, Bipul

AU - Bhat, Abid

AU - Chidambaram, Saravana Babu

AU - Fernandes, Amanda J.

AU - Song, Byoung Joon

AU - Akbar, Mohammed

PY - 2019/4/15

Y1 - 2019/4/15

N2 - Huntington’s disease (HD) is a hereditary neurodegenerative disease of the central nervous system (CNS). Onset of HD occurs between the ages of 30 and 50 years, although few cases are reported among children and elderly. HD appears to be less common in some populations such as those of Japanese, Chinese, and African descent. Clinical features of HD include motor dysfunction (involuntary movements of the face and body, abnormalities in gait, posture and balance), cognitive impairment (obsessive-compulsive disorder), and psychiatric disorders (dementia). Mutation in either of the two copies of a gene called huntingtin (HTT), which codes genetic information for a protein called “huntingtin (Htt)”, precipitates the disease in an individual. Expansion of cytosine–adenine–guanine (CAG) triplet repeats in the HTT gene results in an abnormal Htt protein. Intracellular neuronal accumulation of the mutated Htt protein (mHtt) causes distinctive erratic movements associated with HD. Further, excessive accumulation of the HTT gene repeats causes abnormal production of reactive oxygen species (ROS) and the ensuing mitochondrial (MT) oxidative stress in neurons. Since there is neither a cure nor a promising strategy to delay onset or progression of HD currently available, therapeutics are mainly focusing only on symptomatic management. Several studies have shown that MT dysfunction-mediated oxidative stress is a key factor for the neurodegeneration observed in HD. Supplementation of antioxidants and nutraceuticals has been widely studied in the management of oxidative damage, an associated complication in HD. Therefore, various antioxidants are used as therapeutics for managing and/or treating HD. The present review aimed at delving into the abnormal cellular changes and energy kinetics of the neurons expressing the mHtt gene and the therapeutic roles of antioxidants in HD.

AB - Huntington’s disease (HD) is a hereditary neurodegenerative disease of the central nervous system (CNS). Onset of HD occurs between the ages of 30 and 50 years, although few cases are reported among children and elderly. HD appears to be less common in some populations such as those of Japanese, Chinese, and African descent. Clinical features of HD include motor dysfunction (involuntary movements of the face and body, abnormalities in gait, posture and balance), cognitive impairment (obsessive-compulsive disorder), and psychiatric disorders (dementia). Mutation in either of the two copies of a gene called huntingtin (HTT), which codes genetic information for a protein called “huntingtin (Htt)”, precipitates the disease in an individual. Expansion of cytosine–adenine–guanine (CAG) triplet repeats in the HTT gene results in an abnormal Htt protein. Intracellular neuronal accumulation of the mutated Htt protein (mHtt) causes distinctive erratic movements associated with HD. Further, excessive accumulation of the HTT gene repeats causes abnormal production of reactive oxygen species (ROS) and the ensuing mitochondrial (MT) oxidative stress in neurons. Since there is neither a cure nor a promising strategy to delay onset or progression of HD currently available, therapeutics are mainly focusing only on symptomatic management. Several studies have shown that MT dysfunction-mediated oxidative stress is a key factor for the neurodegeneration observed in HD. Supplementation of antioxidants and nutraceuticals has been widely studied in the management of oxidative damage, an associated complication in HD. Therefore, various antioxidants are used as therapeutics for managing and/or treating HD. The present review aimed at delving into the abnormal cellular changes and energy kinetics of the neurons expressing the mHtt gene and the therapeutic roles of antioxidants in HD.

UR - http://www.scopus.com/inward/record.url?scp=85059837280&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059837280&partnerID=8YFLogxK

U2 - 10.1007/s12640-018-9989-9

DO - 10.1007/s12640-018-9989-9

M3 - Review article

VL - 35

SP - 739

EP - 774

JO - Neurotoxicity Research

JF - Neurotoxicity Research

SN - 1029-8428

IS - 3

ER -

Essa MM, Moghadas M, Ba-Omar T, Walid Qoronfleh M, Guillemin GJ, Manivasagam T et al. Protective Effects of Antioxidants in Huntington’s Disease: an Extensive Review. Neurotoxicity Research. 2019 Apr 15;35(3):739-774. https://doi.org/10.1007/s12640-018-9989-9